BPA for unittuxin, remodulin, tyvaso, orenitram
Active Awarded Last action
- Contract number
- 36E79725A0013
- Awardee
-
United Therapeutics Corp UEI KK5FBFA43JS7
- Awarding agency
-
National Acquisition Center
Headquarters, Department of Veterans Affairs
- Task orders
- 0
Award facts
- Opportunity
-
- VA797P12Q0002 Solicitation number
- Last date to order 75% complete
- IDV ceiling
- $207,127,385.00
- Award type
- Single award
- Who can order
- Only the awarding agency
- Contracting staff
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
Award details come from SAM.gov/FPDS.
About this IDV
United Therapeutics Corp, a biotechnology manufacturer specializing in rare and life-threatening medical treatments, was awarded a single-award Blanket Purchase Agreement by the Department of Veterans Affairs National Acquisition Center valued at $207.1 million with a ceiling date of April 23, 2027. The BPA, awarded on April 24, 2025, operates under the General Services Administration's Federal Supply Schedule for Pharmaceuticals and Drugs (FSS-61-IB) and encompasses four critical pharmaceutical products: Unituxin (chemotherapy agent), Remodulin (subcutaneous injection), Tyvaso (treprostinil inhalation solution in multiple formulations), and Orenitram (oral tablets). The contract utilizes no set-asides and establishes firm fixed-price delivery orders that enable Veterans Integrated Service Networks across the country to procure these specialized medications at pre-negotiated rates without competition. As the sole provider under this BPA, United Therapeutics supplies these products exclusively to the Department of Veterans Affairs, which serves as the primary customer and funding agency.
The contracted pharmaceutical products are primarily designed to treat pulmonary arterial hypertension and select oncology conditions affecting the veteran population. Through the indefinite delivery vehicle structure, the Veterans Health Administration can efficiently manage supply chains for these critical therapeutic agents across its integrated healthcare network nationwide. The BPA allows flexibility in order quantities and timing while maintaining cost predictability, supporting the VA's mission to ensure reliable access to specialized medications at Veterans Integrated Service Networks including VISN 5, VISN 6, VISN 19, VISN 20, VISN 21, VISN 22, and VISN 23. This single-award structure streamlines the procurement process, enabling rapid fulfillment of delivery orders to multiple VA medical facilities while ensuring consistent availability of these essential life-sustaining treatments to veterans.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Exercise an Option | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Other Administrative Action | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Original award | $0 |
Quick answers
Who was awarded contract 36E79725A0013?
36E79725A0013 was awarded to United Therapeutics Corp by National Acquisition Center (Headquarters) on April 24, 2025.
How much is contract 36E79725A0013 worth?
36E79725A0013's own ceiling is $207,127,385.
Who can order from contract 36E79725A0013?
36E79725A0013 is a single award blanket purchase agreement. Only the awarding agency can place orders on it.
Is contract 36E79725A0013 under another contract?
Yes. 36E79725A0013 is a blanket purchase agreement under 36F79720D0104, a federal supply schedule, on Pharmaceuticals and Drugs (FSS-61-IB).
Was contract 36E79725A0013 competed?
The extent of competition for 36E79725A0013 was full and open competition. The government received 1 offer.
On GovTribe
See this IDV's full record
- Every order and transaction
- The awardee's other awards and teaming partners
- Similar IDVs and recompete opportunities
- Ask GovTribe AI about this IDV